Frequently Asked Questions
The market is segmented based on , By Technology (Chromogenic In Situ Hybridization (CISH) and Fluorescence In Situ Hybridization (FISH)), Application (Immunology, Microbiology, Cancer Diagnostic, Neuroscience, and Infectious Disease), Type (DNA and RNA), Product (Instruments, Probes and Kits), End user (Biotechnology/Pharmaceutical Companies, Academic and Research Institutes, and Molecular Diagnostic Labs) – Industry Trends and Forecast to 2030.
.
The Global In Situ Hybridization Market size was valued at USD 1003.50 USD Million in 2022.
The Global In Situ Hybridization Market is projected to grow at a CAGR of 11.5% during the forecast period of 2023 to 2030.
The major players operating in the market include
- Abbott, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific , Merck KGaA, Agilent Technologies , PerkinElmer , Danaher, BioGenex, Advanced Cell Diagnostics , Bio SB, Leica Biosystems Nussloch GmbH, Oxford Gene Technology, Medtronic, GENERAL ELECTRIC, Siemens, Koninklijke Philips N.V., IMRIS, NeuroLogica Corp., Ziehm Imaging GmbH
.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
